COMP <GO>
TNGX vs UNH // EV/EBITDA & P/E VALUATION
Tango Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: TNGX 4
— UNH 10
■ METRIC PARITY
LAST: $22.72 (+0.84%) • MKT CAP: $3.80B
valuation
—
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNGX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TNGX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.90% | 11.47% | -40.37 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.68% | 6.48% | -10.16 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.14% | -63.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 48.30% | 6.46% | +41.84 | TNGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.12 | +22.88 | TNGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.74% | -0.24 | TNGX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 56.0 | -9.36 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.33 | +0.54 | TNGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 17.1x | +10.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.80B | $364.66B | -$360.86B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TNGX REV | UNH REV | TNGX GROSS % | UNH GROSS % | TNGX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.4M | $447.57B | 44.0% | 88.7% | -$139.9M | $16.07B |
| FY 2024 | $42.1M | $400.28B | 44.0% | 88.3% | -$132.3M | $20.70B |
| FY 2023 | $36.5M | $371.62B | 44.0% | 89.6% | -$119.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNGX // BETA 0.87
UNH // BETA 0.33